Phase 2Completed

A Study to Assess the Long-term Safety and Tolerability of TMC114/Rtv in HIV-1 Infected Participants After Rolling-over From Other TMC114 Trials

An Open Label Trial of TMC114/Rtv in HIV-1 Infected Subjects Who Were Randomized in the Trials TMC114-C201, TMC114-C207 or in Sponsor Selected Phase I Trials

Sponsor
Tibotec Pharmaceuticals, Ireland (Industry)
Enrollment
52 enrolled
Conditions
HIV
Interventions
TMC114; rtv
Ages
adults, older adults
Registry
NCT02187107

Full record on ClinicalTrials.gov

From the registry

The purpose of this study was primarily to assess the long-term safety and tolerability of TMC114/rtv in addition to an individually optimized background antiretroviral therapy in HIV-1 infected participants. In addition, antiviral activity and immunological effect were also evaluated.

Primary outcomes

  • Number of participants with adverse events as a measure of safety and tolerability of TMC114/RTV 600/100 mg combination

History

  1. Last registry update

  2. Registered

  3. Study completion

  4. Primary completion

  5. Started